person · Reporting owner

FRATES JAMES M

Disclosed activity across 3 companies

Tapewire entity: 21224
SEC CIK: 0001235598

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alkermes plc.ALKS · Entity 2392	SVP, Alks Inc; CFO ALKS	May 14, 2020	May 14, 2020
Amylyx Pharmaceuticals, Inc.AMLX · Entity 259	Chief Financial Officer	September 10, 2026	September 14, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alkermes plc.

Report date May 14, 2020 · Filed May 14, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	91,828	Reported balance After 2020-05-14 transaction · row 1 1 source row Row 1 · 2020-05-14 · Exercise / conversion · Acquired 21,983 · Balance 91,828
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2020-05-17	Direct	0	Reported balance After 2020-05-14 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-05-14 · Exercise / conversion · Disposed 21,983 · Balance 0 F3: These options are fully vested in accordance with their terms.
Ordinary SharesSEC Table I · non-derivative	IndirectBy 2018 GRAT No. 2	1,669	Reported balance Holding disclosure · report date 2020-05-14 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,669 F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2.
Ordinary SharesSEC Table I · non-derivative	IndirectBy 2019 GRAT No. 1	150,000	Reported balance Holding disclosure · report date 2020-05-14 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 150,000 F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Sons	4,000	Reported balance Holding disclosure · report date 2020-05-14 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 4,000

Filing footnotes · ownership attribution and instrument terms

F1: Shares held by James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2"). The Reporting Person is a trustee and beneficiary of the 2018 GRAT No. 2 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2018 GRAT No. 2.

F2: Shares held by the 2019 GRAT No. 1. The Reporting Person is a trustee and beneficiary of the 2019 GRAT No. 1 and may be deemed to hold voting and dispositive power with regard to the reported shares held by the 2019 GRAT No. 1.

F3: These options are fully vested in accordance with their terms.

Amylyx Pharmaceuticals, Inc.

Report date September 10, 2026 · Filed September 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	233,625	Ending reported balance After 2026-09-10 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-10 · Sale · Disposed 9,768 · Balance 234,667 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Row 2 · 2026-09-10 · Sale · Disposed 1,042 · Balance 233,625 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Common StockSEC Table I · non-derivative	IndirectBy Trust	100,000	Reported balance Holding disclosure · report date 2026-09-10 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100,000 F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	15,459	Reported balance Holding disclosure · report date 2026-09-10 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 15,459 F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	11,072	Reported balance Holding disclosure · report date 2026-09-10 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 11,072 F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
Common StockSEC Table I · non-derivative	IndirectBy Trust	40,000	Reported balance Holding disclosure · report date 2026-09-10 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 40,000 F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805 to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: Shares held by the JAMES M. FRATES 2025 GRAT NO 1 U/A DTD 12/12/2025, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F5: Shares held by the James M. Frates 2024 Grantor Retained Annuity Trust No. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F6: Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

F7: Shares held by the JAMES M. FRATES 2026 GRANTOR RETAINED ANNUITY TRUST NO. 1, for which the Reporting Person serves as trustee and is the sole annuitant. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Sage Therapeutics, Inc.

Report date July 31, 2025 · Filed July 31, 2025

Section 16 reporting ended · disclosed 2025-07-31. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-07-31 transaction · row 1 1 source row Row 1 · 2025-07-31 · Other · Disposed 2,845 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2035-01-03	Direct	Reported balance After 2025-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-07-31 · Disposition to issuer · Disposed 19,154 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2035-06-10	Direct	Reported balance After 2025-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-31 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes.

F2: (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 16, 2019 Filed Feb 19, 2019 23:53 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	3,375	$0.00	$0.00	Disclosure SEC source: 0001127602-19-006969 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 23, 2019 Filed Jan 24, 2019 22:44 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $8.92	$0.00	Disclosure SEC source: 0001562180-19-000492 · primarydocument.xml · derivative · entry 3 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,309 Underlying: Common Stock · 7,500 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested 33% on the first anniversary of the grant date and quarterly thereafter, such that 100% of the shares subject to the option were fully vested and exercisable on May 26, 2017. Read SEC document
January 23, 2019 Filed Jan 24, 2019 22:44 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	7,500	$134.81	$1,011,075.00	Disclosure SEC source: 0001562180-19-000492 · primarydocument.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,235 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
January 23, 2019 Filed Jan 24, 2019 22:44 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	7,500	$8.92	$66,900.00	Disclosure SEC source: 0001562180-19-000492 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 07, 2018 Filed Dec 12, 2018 00:36 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	2,445	$34.01	$83,154.45	Disclosure SEC source: 0001127602-18-035951 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,289 Read SEC document
December 07, 2018 Filed Dec 12, 2018 00:36 UTC	Alkermes plc. ALKS · Entity 2392	GrantOrdinary Shares	5,500	$0.00	$0.00	Disclosure SEC source: 0001127602-18-035951 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,734 F1 · price: These shares were acquired by the reporting person as a result of the partial vesting of performance-vesting restricted stock units granted to the reporting person on February 17, 2017. The vesting of this portion of the performance-vesting restricted stock units was triggered by ALKS 3831 achieving the pre-specified primary efficacy endpoints in each of two phase 3 studies. Read SEC document
August 22, 2018 Filed Aug 23, 2018 21:20 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	65	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-18-003761 · primarydocument.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,235 F2 · price: On August 22, 2018, the reporting person made a charitable gift of 65 shares. No compensation was given to the reporting person for the gifted shares. Read SEC document
August 22, 2018 Filed Aug 23, 2018 21:20 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GiftCommon Stock	700	Not disclosed	Not disclosed	Disclosure SEC source: 0001562180-18-003761 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 F1 · price: On August 22, 2018, the reporting person made a charitable gift of 700 shares. No compensation was given to the reporting person for the gifted shares. Read SEC document
June 12, 2018 Filed Jun 14, 2018 00:26 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	16,842	$50.00	$842,179.16	Disclosure SEC source: 0001127602-18-020855 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,234 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/6/18. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Includes 14,736 shares received on May 1, 2018 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust dated March 14, 2014 (the "2014 GRAT"), which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. F4 · balance_after: Excludes 45,000 shares previously owned directly which were contributed to the James M. Frates 2018 Grantor Retained Annuity Trust No. 2 dated May 25, 2018 (the "2018 GRAT No. 2") on May 29, 2018, which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document
June 06, 2018 Filed Jun 8, 2018 20:03 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $154.06	$0.00	Disclosure SEC source: 0001562180-18-002927 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 6, 2019 or the day immediately prior to the 2019 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 08, 2018 Filed May 8, 2018 20:51 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionStock Option (Right to Buy) · Derivative	7,000	$0.00 Strike: $8.92	$0.00	Disclosure SEC source: 0001562180-18-002370 · primarydocument.xml · derivative · entry 3 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,809 Underlying: Common Stock · 7,000 shares Expires 2024-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Shares vest 25% on first anniversary of grant and quarterly thereafter beginning on May 26, 2014. Read SEC document
May 08, 2018 Filed May 8, 2018 20:51 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	SaleCommon Stock	7,000	$154.00	$1,078,000.00	Disclosure SEC source: 0001562180-18-002370 · primarydocument.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document
May 08, 2018 Filed May 8, 2018 20:51 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	Exercise / conversionCommon Stock	7,000	$8.92	$62,440.00	Disclosure SEC source: 0001562180-18-002370 · primarydocument.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 03, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,813	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-010210 · form4.xml · derivative · entry 9 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This RSU award is fully vested in accordance with its terms. F4 · derivative.expiration_date: This RSU award is fully vested in accordance with its terms. Read SEC document
March 03, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,029	$60.05	$61,791.45	Disclosure SEC source: 0001127602-18-010210 · form4.xml · nonDerivative · entry 4 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,340 Read SEC document
March 03, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,813	$0.00	$0.00	Disclosure SEC source: 0001127602-18-010210 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-010210 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document
March 01, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,326	$57.41	$76,125.66	Disclosure SEC source: 0001127602-18-010210 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,556 Read SEC document
March 01, 2018 Filed Mar 5, 2018 23:02 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	4,500	$0.00	$0.00	Disclosure SEC source: 0001127602-18-010210 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 26, 2018 Filed Feb 28, 2018 23:18 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,625	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-009194 · form4.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,625 Underlying: Ordinary Shares · 2,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/26/2016. Read SEC document
February 26, 2018 Filed Feb 28, 2018 23:18 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	774	$58.12	$44,984.88	Disclosure SEC source: 0001127602-18-009194 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,382 Read SEC document
February 26, 2018 Filed Feb 28, 2018 23:18 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,625	$0.00	$0.00	Disclosure SEC source: 0001127602-18-009194 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11,421 shares received on February 22, 2018 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust No. 2 dated November 25, 2015 (the "2015 GRAT No. 2") which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. F2 · balance_after: Excludes 80,000 shares previously owned directly which were contributed to the James M. Frates 2018 Grantor Retained Annuity Trust No. 1 dated February 22, 2018 (the "2018 GRAT No. 1") on February 23, 2018, which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document
February 17, 2018 Filed Feb 21, 2018 22:55 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	3,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-007600 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18. Read SEC document
February 17, 2018 Filed Feb 21, 2018 22:55 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	929	$67.26	$62,484.54	Disclosure SEC source: 0001127602-18-007600 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,110 Read SEC document
February 17, 2018 Filed Feb 21, 2018 22:55 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	3,000	$0.00	$0.00	Disclosure SEC source: 0001127602-18-007600 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2018 Filed Feb 21, 2018 22:55 UTC	Alkermes plc. ALKS · Entity 2392	GrantEmployee Stock Option (Right to Buy) · Derivative	54,500	$0.00 Strike: $67.26	$0.00	Disclosure SEC source: 0001127602-18-007600 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,500 Underlying: Ordinary Shares · 54,500 shares Expires 2028-02-16 F4 · derivative.exercise_date: Shares subject to the stock option award vest in four equal annual installments commencing on 2/16/2019. Read SEC document
February 16, 2018 Filed Feb 21, 2018 22:55 UTC	Alkermes plc. ALKS · Entity 2392	GrantRestricted Stock Unit Award · Derivative	13,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-18-007600 · form4.xml · derivative · entry 6 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Ordinary Shares · 13,500 shares Expires not disclosed F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19. Read SEC document
December 15, 2017 Filed Sep 17, 2019 23:06 UTC	Alkermes plc. ALKS · Entity 2392	GiftOrdinary Shares	2,000	$0.00	$0.00	Disclosure SEC source: 0001127602-19-028600 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,256 F1 · balance_after: Includes (a) 80,000 shares transferred to the Reporting Person on June 3, 2019 to satisfy an annuity payment from the Reporting Person's 2018 GRAT No. 1 (the James M. Frates Grantor Retained Annuity Trust dated February 22, 2018 and funded on February 23, 2018), and (b) 17,204 shares transferred to the Reporting Person on June 10, 2019 to satisfy an annuity payment from the Reporting Person's 2014 GRAT (the James M. Frates Grantor Retained Annuity Trust dated December 19, 2013 and funded on March 14, 2014), and (c) 43,331 shares transferred to the Reporting Person on June 11, 2019 to satisfy an annuity payment from the Reporting Person's 2018 GRAT No. 2 (the James M. Frates Grantor Retained Annuity Trust dated May 25, 2018 and funded on May 29, 2018), and excludes 150,000 shares previously owned directly, which were contributed on June 14, 2019 to the 2019 GRAT No. 1 (the James M. Frates 2019 Grantor Retained Annuity Trust No. 1 dated June 13, 2019), each of which transactions was exempt from the reporting obligations of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), by virtue of Rule 16a-13 promulgated thereunder. Read SEC document
November 29, 2017 Filed Nov 30, 2017 23:18 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	20,932	$0.00 Strike: $12.29	$0.00	Disclosure SEC source: 0001127602-17-033569 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 20,932 shares Expires 2018-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. F6 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 29, 2017 Filed Nov 30, 2017 23:18 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	400	$51.25	$20,500.00	Disclosure SEC source: 0001127602-17-033569 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,039 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. Read SEC document
November 29, 2017 Filed Nov 30, 2017 23:18 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	20,532	$50.49	$1,036,748.97	Disclosure SEC source: 0001127602-17-033569 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,439 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document
November 29, 2017 Filed Nov 30, 2017 23:18 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	20,932	$12.29	$257,254.28	Disclosure SEC source: 0001127602-17-033569 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. Read SEC document
November 08, 2017 Filed Nov 9, 2017 22:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	20,932	$0.00 Strike: $12.29	$0.00	Disclosure SEC source: 0001127602-17-031773 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,932 Underlying: Ordinary Shares · 20,932 shares Expires 2018-05-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. F7 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
November 08, 2017 Filed Nov 9, 2017 22:07 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	20,932	$47.58	$996,009.45	Disclosure SEC source: 0001127602-17-031773 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,039 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.06 to $48.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document
November 08, 2017 Filed Nov 9, 2017 22:07 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	20,932	$12.29	$257,254.28	Disclosure SEC source: 0001127602-17-031773 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 6/9/17. Read SEC document
June 09, 2017 Filed Nov 9, 2017 22:07 UTC	Alkermes plc. ALKS · Entity 2392	GiftOrdinary Shares	2,000	$0.00	$0.00	Disclosure SEC source: 0001127602-17-031773 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,477 F1 · balance_after: Includes 16,562 shares received on August 1, 2017 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust dated May 29, 2015 (the "2015 GRAT"), which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document
June 07, 2017 Filed Jun 8, 2017 23:38 UTC	Sage Therapeutics, Inc. SAGE · Entity 77038	GrantStock Option (Right to Buy) · Derivative	14,000	$0.00 Strike: $72.74	$0.00	Disclosure SEC source: 0001562180-17-002238 · primarydocument.xml · derivative · entry 1 FRATES JAMES M · CIK 0001235598 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date. Read SEC document
May 28, 2017 Filed May 30, 2017 21:39 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-019713 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This RSU award is fully vested in accordance with its terms. F5 · derivative.expiration_date: This RSU award is fully vested in accordance with its terms. Read SEC document
May 28, 2017 Filed May 30, 2017 21:39 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,177	$57.70	$67,912.90	Disclosure SEC source: 0001127602-17-019713 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,477 Read SEC document
May 28, 2017 Filed May 30, 2017 21:39 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,500	$0.00	$0.00	Disclosure SEC source: 0001127602-17-019713 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9,101 shares received on March 20, 2017 pursuant to an annuity payment from the James M. Frates Grantor Retained Annuity Trust dated March 14, 2014 (the "2014 GRAT"), which was exempt from reporting obligations by virtue of Rule 16a-13 promulgated under the Securities Exchange Act of 1934, as amended. Read SEC document
March 07, 2017 Filed Mar 7, 2017 22:29 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $16.55	$0.00	Disclosure SEC source: 0001127602-17-010657 · form4.xml · derivative · entry 8 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,958 Underlying: Ordinary Shares · 25,000 shares Expires 2022-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · derivative.exercise_date: These options are fully vested in accordance with their terms. Read SEC document
March 07, 2017 Filed Mar 7, 2017 22:29 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	400	$59.57	$23,828.00	Disclosure SEC source: 0001127602-17-010657 · form4.xml · nonDerivative · entry 3 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,053 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.51 to $59.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document
March 07, 2017 Filed Mar 7, 2017 22:29 UTC	Alkermes plc. ALKS · Entity 2392	SaleOrdinary Shares	24,600	$59.07	$1,453,240.08	Disclosure SEC source: 0001127602-17-010657 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,453 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.49 to $59.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document
March 07, 2017 Filed Mar 7, 2017 22:29 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	25,000	$16.55	$413,750.00	Disclosure SEC source: 0001127602-17-010657 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document
March 03, 2017 Filed Mar 6, 2017 22:37 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	2,812	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-010467 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,813 Underlying: Ordinary Shares · 2,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/3/2015. Read SEC document
March 03, 2017 Filed Mar 6, 2017 22:37 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	913	$60.97	$55,665.61	Disclosure SEC source: 0001127602-17-010467 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,053 Read SEC document
March 03, 2017 Filed Mar 6, 2017 22:37 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	2,812	$0.00	$0.00	Disclosure SEC source: 0001127602-17-010467 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2017 Filed Mar 2, 2017 23:04 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionRestricted Stock Unit Award · Derivative	4,500	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-17-009854 · form4.xml · derivative · entry 7 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Ordinary Shares · 4,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017. Read SEC document
March 01, 2017 Filed Mar 2, 2017 23:04 UTC	Alkermes plc. ALKS · Entity 2392	Tax withholdingOrdinary Shares	1,461	$59.71	$87,236.31	Disclosure SEC source: 0001127602-17-009854 · form4.xml · nonDerivative · entry 2 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,154 Read SEC document
March 01, 2017 Filed Mar 2, 2017 23:04 UTC	Alkermes plc. ALKS · Entity 2392	Exercise / conversionOrdinary Shares	4,500	$0.00	$0.00	Disclosure SEC source: 0001127602-17-009854 · form4.xml · nonDerivative · entry 1 FRATES JAMES M · CIK 0001235598 · SVP, Alks Inc; CFO ALKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.